Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Updates in CAR-T for non-Hodgkin lymphoma

In this video, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, summarizes the key updates in CAR-T therapy for the treatment of non-Hodgkin lymphoma. Dr Collins highlights three studies from the 2021 ASH conference that focus on CAR-T therapy in first relapse for B-cell lymphoma: ZUMA-7, BELINDA, and TRANSFORM (NCT03391466, NCT03570892, NCT03575351). In his discussion, Dr Collins discusses and compares the results and subtle differences in these studies, including primary endpoints and outcomes. Following this, Dr Collins focuses his interest on the ZUMA-12 study (NCT03761056), explaining the methodology and results. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.